Pressemeldinger

Bristol-Myers Squibb får positiv CHMP-vurdering for Daklinza® (daclatasvir) for behandling av kronisk hepatitt C i EU

30-06-2014 14:00 CEST Bristol-Myers Squibb

02-06-2014 14:00 CEST Bristol-Myers Squibb

 In Phase 2 and 1b Renal Cell Carcinoma Trials, Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Showed Antitumor Activity as a Single Agent and in Combination Regimen with Yervoy® (ipilimumab)

16-05-2014 10:17 CEST Bristol-Myers Squibb

Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Showed Antitumor Activity in Previously Treated and Chemotherapy-Naïve Patients in Phase 1b                                             Non-Small Cell Lung Cancer Trials

16-05-2014 10:13 CEST Bristol-Myers Squibb

Bristol-Myers Squibb Announces Two- and Three-Year Survival Data for Nivolumab, an Investigational PD-1 Immune Checkpoint Inhibitor, from Advanced Melanoma Cohort of a Phase 1b Study

16-05-2014 09:48 CEST Bristol-Myers Squibb • Across doses (n=107), 48% and 41% of this heavily pre-treated patient population that received nivolumab as a single agent was alive at two and three years, respectively • Spectrum, frequency and severity of treatment-related adverse events from this study were consistent with those initially reported for these patients in prior publications

Bristol- Myers Squibb presenterer data for et legemiddel i perorale kombinasjoner på tvers av ulike genotyper av hepatitt C på The International Liver Congress

24-03-2014 15:46 CET Bristol-Myers Squibb

17-01-2014 16:36 CET Gilead

Europeiske legemiddelmyndigheter fremskynder regulatorisk gjennomgang av søknad om markedsføringstillatelse for legemiddel til behandling av kronisk hepatitt C

08-01-2014 13:24 CET Bristol-Myers Squibb

25-11-2013 18:35 CET Gilead Foster City, CA, 22. november, 2013 – Gilead Sciences, Inc. (Nasdaq: GILD) kunngjorde i dag at Komitéen for humane legemidler (Committee for Medicinal Products for Human Use – CHMP), tilknyttet EUs legemiddeltilsyn (European Medicines Agency – EMA), har kommet med en positiv uttalelse vedrørende selskapets søknad om markedsføringstillatelse (MT) for Sovaldi®- (sofosbuvir, 400 mg tabletter)

7 av 10 barn og unge sliter med sprøyter!

07-11-2013 08:00 CET ConceptoMed AS